These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

203 related items for PubMed ID: 31665480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
    Nauck M, Schmidt WE, Ebert R, Strietzel J, Cantor P, Hoffmann G, Creutzfeldt W.
    J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
    [Abstract] [Full Text] [Related]

  • 8. Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man.
    Ahrén B, Pettersson M, Uvnäs-Moberg K, Gutniak M, Efendic S.
    Diabetes Res Clin Pract; 1991 Sep; 13(3):153-61. PubMed ID: 1683622
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Glucose dependent insulinotropic polypeptide (GIP) infused intravenously is insulinotropic in the fasting state in type 2 (non-insulin dependent) diabetes mellitus.
    Jones IR, Owens DR, Luzio S, Hayes TM.
    Horm Metab Res; 1989 Jan; 21(1):23-6. PubMed ID: 2647605
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A supplementary infusion of glucose-dependent insulinotropic polypeptide (GIP) with a meal does not significantly improve the beta cell response or glucose tolerance in type 2 diabetes mellitus.
    Jones IR, Owens DR, Vora J, Luzio SD, Hayes TM.
    Diabetes Res Clin Pract; 1989 Nov 06; 7(4):263-9. PubMed ID: 2693029
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.
    J Clin Endocrinol Metab; 1993 Apr 06; 76(4):912-7. PubMed ID: 8473405
    [Abstract] [Full Text] [Related]

  • 19. Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.
    Meier JJ, Nauck MA, Kask B, Holst JJ, Deacon CF, Schmidt WE, Gallwitz B.
    World J Gastroenterol; 2006 Mar 28; 12(12):1874-80. PubMed ID: 16609993
    [Abstract] [Full Text] [Related]

  • 20. Cephalic phase secretion of insulin and other enteropancreatic hormones in humans.
    Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, Vilsbøll T, Holst JJ.
    Am J Physiol Gastrointest Liver Physiol; 2016 Jan 01; 310(1):G43-51. PubMed ID: 26492921
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.